Advertisement

Topics

Companies Related to "Related Macular Degeneration Pipeline Review 2017 Report Updated" [Most Relevant Company Matches] RSS

11:38 EST 19th February 2019 | BioPortfolio

Here are the most relevant search results for "Related Macular Degeneration Pipeline Review 2017 Report Updated" found in our extensive corporate database of over 50,000 company records.

Showing "Related Macular Degeneration Pipeline Review 2017 Report Updated" Companies 1–25 of 3,200+

Extremely Relevant

Ocata Therapeutics, Inc.

Ocata Therapeutics, Inc. is a clinical stage biotechnology company focused on the development and commercialization of Regenerative Ophthalmology therapeutics. Ocata’s most advanced products are in clinical trials for the treatment of Stargardt’s macular degeneration, dry age-related macular degeneration, and myopic macular degeneration. Ocataâ...


Ocata Therapeutics, Inc.

Ocata Therapeutics, Inc. is a clinical stage biotechnology company focused on the development and commercialization of regenerative ophthalmology therapeutics. Ocata’s most advanced products are in clinical trials for the treatment of Stargardt’s macular degeneration, dry age-related macular degeneration, and myopic macular degeneration. Ocataâ...

Georgia Retina, P.C.

The physicians of Georgia Retina specialize in the diagnosis and treatment of diabetic retinopathy, macular pucker and macular holes, age-related macular degeneration, retinal detachment, proliferative vitreoretinopathy, ocular trauma, hereditary macular disease, retinopathy of prematurity and other forms of retinal and vitreous pathologies.


BioMolecular Therapeutics, Inc.

An early-stage biopharmaceutical company, BMT is pioneering the development of novel RNAi therapeutics to prevent and treat age-related macular degeneration based on the company's proprietary technology, asymmetric shorter-duplex siRNA (asiRNA). This novel RNAi technology significantly reduces deleterious side effects triggered by conventional siRNA, especially, the stimulation of the innate immun...

Guardion Health Sciences, Inc.

Guardion Health Sciences, Inc. is an ocular health sciences company that develops, formulates and distributes condition-specific medical foods, with an initial medical food product that addresses a depleted macular protective pigment, a known risk factor for age-related macular degeneration (“AMD”), and a significant component of functional vision ...

Relevant

Retina Associates of Florida

Retina Associates is a state-of-the art diagnostic and treatment center as well as a leading clinical research center for macular degeneration and other retinal diseases. Its physicians are Mark Hammer, MD, Ivan Suñer, MD and Marc Peden, MD who are consistently voted "Best Doctors in America." Retina Associates of Florida has pioneered several procedures ...

Allegro Ophthalmics, LLC

With more than 100 years of combined experience in vision science and medicine, the leadership team at Allegro Ophthalmics, LLC is establishing Integrin Peptide Therapy as the next-generation pharmaceutical category for the treatment of wet age-related macular degeneration, diabetic retinopathy and diabetic macular edema, which together affect nearly si...

Optherion, Inc.

Optherion, Inc. is a private, innovative biotechnology company that is developing protein therapeutics and molecular diagnostics for the management of dry and wet Age-related Macular Degeneration (AMD) and other chronic diseases involving the alternative complement system. Optherion's proprietary technologies are based on landmark scientific discoveries linking certain genes to AMD.

Icon Bioscience, Inc.

Icon Bioscience, Inc., (IBI), is a privately held biopharmaceutical company that specializes in the development and commercialization of novel ophthalmic pharmaceuticals based on its Verisome(TM) drug delivery technology. IBI is developing a broad portfolio of clinically superior specialty pharmaceuticals targeting major ophthalmic indications including macular edema, glaucoma, age-related macula...

Active Pass Pharmaceuticals

Active Pass' mission is to be the industry leader in the discovery and development of small-molecule drugs that target human ABC transporters. A family of 48 structurally-related molecular pumps, ABC transporters are targets for diseases with substantial markets including age-related macular degeneration, lipid disorders, Alzheimer's disease, and type II diabetes. Our competitive advantage derives...

Neurotech USA, Inc

Neurotech is a biotechnology company dedicated to the development of sight-saving therapeutics for chronic retinal diseases. Retinal diseases represent significant unmet medical needs for which new medical therapies are the largest market opportunity in ophthalmology. Neurotech’s lead product (NT-501) is in clinical development for the treatment of retinal degeneration, including retinitis pigme...

Aciont Inc.

AciontTM Inc. endeavors to become the world leader in commercializing localized, non-invasive and controlled release back-of-the-eye therapeutics for sight threatening diseases. Our name Aciont ("action transport therapeutics") refers to our expertise in controlling drug transport through human membrane tissues. Our Visulex TM technology provides ophthalmologists (and potentially patients thems...

Ångstrom Pharmaceuticals, Inc.

Ångstrom Pharmaceuticals, Inc. is a venture-backed pharmaceutical company. Ångstrom’s proprietary products target a clearly-defined pathway, the Urokinase Plasminogen Activation System (PA), which has repeatedly been shown in scientific literature to be directly involved in proliferative diseases, such as cancer and wet age-related macular degeneration (ARMD). The Company’s lead product, ...

Kinexis Inc

Kinexis, Inc. is a life science R&D company creating pharmaceutical and biopharmaceutical product opportunities based on promising early-stage inventions from academic institutions. Predictive animal models of human disease are employed to interrogate product concepts and validate product opportunities. Kinexis’ ultimate objective is to create a renewable pipeline of pre-clinical drug developme...

Othera Pharmaceuticals

Othera Pharmaceuticals, Inc. is a privately-held U.S. specialty pharmaceutical company focused on the development of innovative new drugs to treat the leading causes of blindness and vision impairment:Dry and wet forms of age-related macular degeneration (AMD) Cataracts Glaucoma Dry eye syndrome Founded in 2002, Othera has progressed rapidly and expects to have as many as eight separate Phase 2 cl...

Icon Bioscience Inc.

Icon Bioscience, Inc. is a privately held specialty biopharmaceutical company focused on the development and commercialization of unique ophthalmic pharmaceuticals based on its patented and proprietary Verisome® drug delivery technology. The technology encompasses a broad number of related, but distinct drug delivery systems capable of incorporating an ...

BioAxone Therapeutic Inc.

BioAxone’s strategy is to become the world’s dominant bio-pharmaceutical company targeting Rho and Rho-related pathways with the purpose of developing drugs that meet large unmet medical needs. Rho being a signaling pathway which plays a key role in many disease indications, BioAxone has successfully developed a protein based inhibitor for local acute administration, as well as a family of sma...

Gene Signal

Gene Signal (www.genesignal.com) is developing a robust pipeline of novel antisense oligonucleotides, proteins and monoclonal antibodies to treat a range of conditions based on its innovative angiogenesis modulating technology. The company’s most advanced therapeutic product is aganirsen (GS-101), an antisense oligonucleotide that has nearly completed...

BioTime Inc.

BioTime is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. BioTime’s pipeline is based on two platform technologies which encompass cell replacement and cell/drug delivery. BioTime’s lead cell replacement product candidate is OpRegen®, a ret...

RetroSense Therapeutics

RetroSense Therapeutics is a biotechnology company developing a game-changing gene therapy to restore vision in patients suffering from blindness due to retinitis pigmentosa (RP) and advanced dry age-related macular degeneration (advanced dry-AMD). There are currently no FDA approved therapies to improve or restore vision in patients with these retinal deg...

RetroSense Therapeutics, LLC

RetroSense Therapeutics is a privately-held biotechnology company developing life-enhancing gene therapies designed to restore vision in patients suffering from blindness due to retinitis pigmentosa (RP) and advanced dry age-related macular degeneration (advanced dry-AMD). There are currently no FDA approved drugs to improve or restore vision in patients w...

Notalâ„¢ Vision Ltd

Notalâ„¢ Vision Inc. was founded in May 2000, by a group of senior ophthalmologists from Israels' leading medical centers.The company is developing the first comprehensive diagnostic solutions for the early detection and frequent monitoring of Age-Related Macular Degeneration (AMD), the leading cause of blindness in the western world today.To address the growing need for early detection of wet...

Advanced Refractive Technologies

Advanced Refractive Technologies is an ophthalmic developmental and marketing company, which is focusing upon the most important areas of need in ophthalmology. The Company is developing both medical devices as well as pharmaceutical agents to be used in important pathologies within the ophthalmology market. These areas include: Cataract detection Cataract surgery Glaucoma therapy Age-...

Eyenuk, Inc.

Eyenuk, Inc., headquartered in Los Angeles, California, is an AI diagnostic company focused on quickly and accurately identifying patients suffering from potentially blinding eye diseases and chronic diseases at the point of care. Using computer vision and machine learning expertise, the company is developing a portfolio of products based on its proprietar...

OcuSciences, Inc.

OcuSciences, Inc., is a clinical-stage biotechnology company developing retinal imagers to identify metabolic dysfunction occurring in the retina for the detection of early disease. Its flagship device, the OcuMet Beacon, is being developed to automatically and non-invasively assess retinal metabolic function by detecting the degree of flavoprotein fluores...


More From BioPortfolio on "Related Macular Degeneration Pipeline Review 2017 Report Updated"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks